Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients

NCT01911520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Morbidly Obese Patients

Interventions

DRUG: Sugammadex 2 mg/kg
DRUG: Sugammadex. 4 mg/kg
PROCEDURE: Neuromuscular monitoring.
PROCEDURE: Clinical evaluation of residual curarization .

Sponsor

University Hospital, Ghent